Burden-Evaluated Active Therapy for AF Using Continuous Wearables BEAT-AF Trial

Inclusion criteria

• Inpatients ≥18 years of age at admission;
• Paroxysmal atrial fibrillation was diagnosed;
• Own a smart phone and a smart watch and be able to operate them basically;
• Before being enrolled, the average daily atrial fibrillation burden was calculated to be ≥ 4.59% based on monitoring through an intelligent wristwatch for at least 3 days;
• The treatment status meets any of the following conditions:

• If anticoagulation therapy is being administered, the treatment plan must be stable for at least 4 weeks;
• If heart rate or rhythm control medications are being used, the treatment plan must be stable for at least 4 weeks;
• Or no specific rhythm control treatment for atrial fibrillation is being received;
• Sign the informed consent form

Exclusion criteria

• Has an implanted pacemaker, implantable cardioverter-defibrillator or cardiac resynchronization therapy device.
• There may be skin diseases, limb deformities or allergies that prevent the proper wearing of wearable devices on the upper limbs.
• Having active mental disorders or cognitive impairments, as well as other conditions that result in lack of or restricted ability to act, and which, in the judgment of the researchers, make it impossible for the subject to comply with the trial protocol.
• During pregnancy, lactation, or planning to become pregnant during the trial period.
• At the same time, participate in other clinical trials that may interfere with the results of this study